TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04674046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Description: Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative treatment
Description: Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education
Description: All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education
Description: All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
Study: NCT02799758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK-104-CR
Description: NK-104-CR 8 mg for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo® IR
Description: Livalo® IR 4 mg daily for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for NK-104-CR)
Description: NK-104-CR 8 mg placebo for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Livalo® IR)
Description: Livalo® IR 4 mg placebo for 52 weeks
Study: NCT01957748

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SoC + ALERT Intervention
Description: Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
Study: NCT02793518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological tests
Study: NCT02620579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol LA (60 mg)
Description: Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol LA (60 mg)
Description: Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
Study: NCT00355186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracoronary bone marrow cells infusion
Description: intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracoronary bone marrow cells infusion
Description: intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described
Study: NCT03756298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study: NCT02990208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
Study: NCT03061110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction
Description: Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will include over-the-counter and prescription methods to treat xerostomia.
Study: NCT01776788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro injection, exenatide injection
Description: First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro injection
Description: Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
Study: NCT02066467

Intervention type: DEVICE
Intervention: Left Ventricular lead implant: ACUITY X4® Lead Family
Description: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
Study: NCT02620579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
Study: NCT04508192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both interventions are simple strength exercises without technical equipment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both interventions are simple strength exercises without technical equipment
Study: NCT01482793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
Study: NCT03689998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: immediate implant placement in freshly extraction socket
Study: NCT03471442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Study: NCT02542956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: receive Exparel by injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: receive Marcaine in a pain pump
Study: NCT03471442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Study: NCT02542956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: receive Marcaine by injection
Study: NCT01399658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy
Description: MRI-guided application of brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-Deoxy-3'-18f-Fluorothymidine
Description: Assessing tumor proliferation in Gynecologic cancer
Study: NCT03885115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
Study: NCT04236934

Intervention type: OTHER
Intervention: Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis
Description: Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
Study: NCT03104712

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #1
Description: 50g available carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #2
Description: 50g available carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #3
Description: 50g available carbohydrate
Study: NCT01099436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT02849015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study: NCT03376685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Training (END)
Description: Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Exercise Training (SIT)
Description: Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
Study: NCT03459365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euflexxa
Description: Aspirations performed before each injection and at six weeks.
Study: NCT03689998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: immediate implant placement in freshly extraction socket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: topical application of melatonin
Study: NCT02206425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study: NCT05179291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy Group
Description: The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Realitiy-VR Group
Description: VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
Study: NCT03216564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Active vitamin D (Calcitriol) 0.25 micrograms
Study: NCT03104712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti
Description: 50g available carbohydrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice
Description: 50g available carbohydrate
Study: NCT01290666

Intervention type: DEVICE
Intervention: Fistula Plug
Description: Bioabsorbable fistula plug
Study: NCT04094922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swedish PTSD Coach smartphone app
Description: Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
Study: NCT04283006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20/CD22 dual Targeted CAR T-cells
Description: Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
Study: NCT04634864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: 40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The stimulator was switched off after 2 minutes of stimulation.
Study: NCT03330431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
Study: NCT04976361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
Description: PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
Study: NCT02763852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
Study: NCT04220372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD